New Journal of Oncology Practice Special Series Focuses on Real-World Approaches to Quality Care

The latest issue of the Journal of Oncology Practice (JOP) features a new Special Series focusing on Real-World Approaches to Quality Improvement in Oncology. The issue includes research and commentary that share practical examples of approaching quality measurement and improvement that can guide physicians and others in the oncology field.

ASCO Submits Statement on 21st Century CURES Act and Health Information Technology has submitted a statement for the record from ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, to the House Energy and Commerce Committee’s Subcommittee on Health related to its recent hearing, “Implementing the 21st Century Cures Act: An Update from the Office of the National Coordinator.”

In Case You Missed It: Watch ASCO’s Webinar on 2019 Medicare Reimbursement Changes

ASCO recently hosted a webinar outlining important changes to Medicare reimbursement starting Jan. 1, 2019. The event, 2019 Medicare Reimbursement – Final Rules Update, provided details on how provisions in the Hospital Outpatient Prospective Payment System (HOPPS), as well as the Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) final rules will impact cancer care in the year ahead.

Federal Funding Update: Fiscal Year 2019

On Friday, December 7, President Trump signed into law a two-week Continuing Resolution (CR) to prevent a partial government shutdown.

While Congress was able to pass some of its Fiscal Year (FY) 2019 appropriations bills before the end of the 2018 fiscal year, it has not yet come to agreement on seven remaining appropriations bills, which fund a variety of federal departments and agencies, including the Food and Drug Administration (FDA). The CR will provide flat funding for those agencies until December 21, 2018, when Congress will need to take further action to fund them.

FDA Approves Atezolizumab With Chemotherapy and Bevacizumab for First-Line Treatment of Metastatic Non-Squamous NSCLC

On December 6, 2018, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech, Inc.), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.

ASCO Urges Amended Language in Pharmaceutical Compounding

ASCO submitted comments to the United States Pharmacopeia Convention (USP) concerning a proposed chapter on pharmaceutical compounding. ASCO is concerned that proposed chapter, General Chapter <797> Pharmaceutical Compounding– Sterile Preparations (USP <797>), as it is currently written, could create unnecessary confusion for providers, interfere with patient access to potentially life-saving drugs, and undermine FDA drug approval requirements.

How Can Financial Barriers to Patient Participation in Clinical Trials Be Addressed?

In the latest ASCO in Action Podcast, Dr. Beverly Moy, a medical oncologist at the Massachusetts General Hospital, joined ASCO CEO Dr. Clifford A. Hudis to discuss patient participation in clinical trials and how policymakers, trial sponsors, and other stakeholders can help remove and overcome financial barriers.

Recent Research Reveals High Financial and Mental Stress Levels Among Caregivers of People Living with Cancer

Research published in the Journal of Oncology Practice (JOP) in November 2018 found that caregivers who provide care for longer hours and at longer durations (high-intensity care) are more likely to have poor mental health. The problem is especially acute for those who lack access to support services. 


Subscribe to ASCO RSS